

# Review of: "Simplifying the dental/periodontal management of patients with metabolic bone fragility receiving treatment with denosumab"

Rosario SERPICO<sup>1</sup>

<sup>1</sup> Università degli Studi della Campania Luigi Vanvitelli

**Potential competing interests:** The author(s) declared that no potential competing interests exist.

There are numerous typos in the text.

Just as an example, in the abstract:

“ Denosumab has benn linked to the occurrence of osteonecrosis of the jaw (MRONJ), a uncommon but severe oral side effect...”

“... on specific risk reduction protocols to eliminate dental/periodontal infections, still protectig from MRONJ onset.”

“...it is likely that the MRONJ risk profile of patients with metabolic bone fragility receiving receiving different ARs could somewhat vary.”